He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.

As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...

Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...

With a market capitalization of $11.47 billion and an "GREAT" financial health score according to InvestingPro, the company's flagship product, Ingrezza, continues to drive impressive revenue ...

Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives. Neurocrine ...

With a market capitalization of $11.47 billion and an "GREAT" financial health score according to InvestingPro, the company's flagship product, Ingrezza, continues to drive impressive revenue growth ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.